Vertex Pharmaceuticals Incorporated
VRTX
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAFTA for the treatment of patients with CF 6 years of aā¦ read more
Healthcare
Biotechnology
34 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$450.41
Price-0.59%
-$2.65
1Y
Price
Market Cap
$114.316b
Large
Price/Earnings 3y Avg5y Avg
26.7x
Premium
Premium
Financial Reports
Key metrics over the past few years and other important metrics. Amounts in USD.+38.1%
EBITDA Margin+34.5%
Net Profit Margin+43.4%
Free Cash Flow Margin+38.1%
EBITDA Margin+34.5%
Net Profit Margin+43.4%
Free Cash Flow MarginRevenue
$12.255b
+1.5%
1y CAGR+7.6%
3y CAGR+8.3%
5y CAGREarnings
$4.338b
+9.7%
1y CAGR+244.3%
3y CAGR+185.5%
5y CAGREPS
$16.86
+10.1%
1y CAGR+243.9%
3y CAGR+185.0%
5y CAGRBook Value
$19.362b
$26.484b
Assets$7.123b
Liabilities$1.987b
DebtDebt to Assets
7.5%
0.4x
Debt to EBITDAFree Cash Flow
$3.710b
+16.2%
1y CAGR+132.1%
3y CAGR+94.9%
5y CAGRNo items found.
Press Releases
Statements and updates from the company